Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | PAK4 | O96013 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30973144 | 1.00 | GRIN2D (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL615808 | 0.86 | POLB (0.53) | KDM4EMETAP2CHEK1AURKADAPK3 | |
| SCHEMBL16208357 | 0.76 | ALDH1A1 (0.56) | KDM4EPOLBMAPTHSD17B10MEN1 | |
| SCHEMBL29874884 | 0.76 | ALDH1A1 (0.56) | KDM4EPOLBMAPTHSD17B10MEN1 | |
| SCHEMBL16627567 | 0.74 | METAP2 (0.46) | METAP2CHEK1AURKADAPK3JAK2 | |
| SCHEMBL10153752 | 0.74 | PARP1 (0.56) | KDM4EMETAP2CHEK1AURKADAPK3 | |
| SCHEMBL18548573 | 0.74 | CYP19A1 (0.49) | METAP2CHEK1AURKADAPK3JAK2 | |
| SCHEMBL4704929 | 0.74 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30807512 | 0.73 | GRIN2D (0.67) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30807513 | 0.73 | GRIN2D (0.67) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198259-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2021-07-01 | — | — | US | disclosed |
| EP-3807282-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2021-04-21 | — | — | EP | disclosed |
| CN-112204032-A | Heterocyclic derivatives and use thereof | C&C新药研究所 | 2021-01-08 | — | — | CN | disclosed |
| US-10249831-B2 | Electronic device containing cyclic lactams | MERCK PATENT GMBH (DE) | 2019-04-02 | — | — | US | disclosed |
| US-20180040832-A1 | ELECTRONIC DEVICE CONTAINING CYCLIC LACTAMS | MERCK PATENT GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2408744-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010107768-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010107768-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10249831-B2 | Electronic device containing cyclic lactams | OXA1L, UROD, MRPL21 | GRIN2D 358/4885GRIN3B 1369/4885GRIN1 660/4885 |
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | GRIN2D 2186/4885GRIN3B 2342/4885GRIN1 1765/4885 |
| US-20180040832-A1 | ELECTRONIC DEVICE CONTAINING CYCLIC LACTAMS | OXA1L, UROD, MRPL21 | GRIN2D 358/4885GRIN3B 1369/4885GRIN1 660/4885 |
| US-20210198259-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | HRH4, HRH2, HRH1 | GRIN2D 1532/4885GRIN3B 1693/4885GRIN1 1205/4885 |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | GRIN2D 1354/4885GRIN3B 1028/4885GRIN1 810/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | GRIN2D 1354/4885GRIN3B 1028/4885GRIN1 810/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | GRIN2D 1354/4885GRIN3B 1028/4885GRIN1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.